Related Experiment Videos
Extracellular CIRP aggravates cardiac dysfunction via the TLR4/MD2-NLRP3 axis during venoarterial ECMO
Huizhen Li1, Junjie Shao2, Jian Li3
1Department of Cardiac Surgery, Lanzhou University Second Hospital, Lanzhou 730030, China; The Second Clinical Medical College of Lanzhou University, Lanzhou University, Lanzhou 730030, Gansu, China; Cuiying Biomedical Research Center, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, China.
Objectives:
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) in patients with cardiogenic shock (CS) inevitably induces systemic ischemia-reperfusion injury, which is accompanied by elevated levels of extracellular cold-inducible RNA-binding protein (CIRP) and an aggravated inflammatory response. However, the specific role of CIRP during VA-ECMO support remains unclear.
Methods:
CS patients undergoing VA-ECMO were enrolled, and serum CIRP expression levels were measured. A myocardial infarction-induced CS rat model with VA-ECMO was established. Myocardial tissue and serum were analyzed by ELISA, immunohistochemistry, and Western blotting. Cardiac function was assessed via echocardiography. CIRP-knockout rats and the CIRP antagonist C23 were used to investigate CIRP's role, and H9c2 cells were utilized to investigate the effects of recombinant CIRP in vitro.
Results:
In VA-ECMO patients, serum CIRP levels were significantly higher in non- survivors compared to survivors. Similarly, in the VA-ECMO-assisted CS rat model,rats with high CIRP expression exhibited greater myocardial injury. Administration of exogenous CIRP significantly exacerbated myocardial injury during VA-ECMO. In contrast, genetic deletion of CIRP attenuated both myocardial injury and inflammation during VA-ECMO. Furthermore, CIRP was associated with activation of the NLRP3 inflammasome and aggravated cardiomyocyte injury. In vivo, treatment with the C23 significantly alleviated myocardial injury and inflammation under VA-ECMO.
Conclusions:
In patients with CS supported by VA-ECMO, elevated serum CIRP levels were significantly associated with poor survival outcomes. CIRP aggravated myocardial injury and inflammation, accompanied by NLRP3 activation.Pharmacological inhibition of CIRP mitigated myocardial damage during VA-ECMO, suggesting its potential as a therapeutic target for attenuating cardiac injury in CS patients.
Related Concept Videos
Cardiomyopathy IV: Restrictive Cardiomyopathy
Rheumatic Heart Disease I: Introduction
Cirrhosis II: Pathophysiology
Heart Failure II: Pathophysiology
Cardiomyopathy II: Dilated Cardiomyopathy
Acute Inflammation III: Local and Systemic Effects